Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics

LONDON, August 13, 2014 /PRNewswire/ --

On Tuesday, August 12, 2014, the NASDAQ Composite ended at 4,389.25, down 0.27%, the Dow Jones Industrial Average finished the session at 16,560.54, down 0.06% and the S&P 500 closed at 1,933.75, down 0.16%. During the trading session, seven out of ten sectors finished on a lower note. The S&P 500 Health Care Sector Index ended the day 0.14% lower at 699.06, and the index has declined 1.94% in the previous one month. Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Novavax Inc. (NASDAQ: NVAX), Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), XOMA Corp. (NASDAQ: XOMA), and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free research on these five companies can be accessed at:  

http://investor-edge.com/register

Exelixis Inc.'s stock fell by 1.89% on Tuesday, ending the session at $4.15. A total of 1.35 million shares were traded, below its three months average volume of 3.87 million shares. The stock moved between $4.14 and $4.23 during the session. Shares in Exelixis Inc. have gained 1.22% in the previous three trading sessions and 24.81% in the last one month. However, the company's shares have lost 32.30% from the beginning of 2014. The company's stock is trading above its 50-day moving average. The stock's 50-day moving average of $3.69 is below its 200-day moving average of $5.02. Moreover, Exelixis Inc.'s stock has a Relative Strength Index (RSI) of 60.44. Sign up and read the free notes on EXEL at:

http://www.Investor-Edge.com/EXEL-13Aug2014

Shares in Novavax Inc. fluctuated between $4.32 and $4.51 before ending Tuesday's session 2.91% lower at $4.34. The stock reported a trading volume of 2.21 million shares, which was below its three months average volume of 3.92 million shares. Novavax Inc.'s stock has advanced 2.84% in the previous three trading sessions, although, the stock has declined 5.03% in the last one month and 15.23% on YTD basis. Shares in Novavax Inc. are trading below their 50-day and 200-day moving averages of $4.54 and $4.61, respectively. Further, the company's shares have an RSI of 50.83. The complimentary notes on NVAX can be downloaded as in PDF format at:

http://www.Investor-Edge.com/NVAX-13Aug2014

On Tuesday, shares in Achillion Pharmaceuticals Inc. recorded a trading volume of 1.99 million shares, much below its three months average volume of 6.50 million shares. The stock finished the day at $7.65, which was 0.79% higher its previous day's closing of $7.59, and registered an intraday range of $7.47 and $7.75. Shares in Achillion Pharmaceuticals Inc. have advanced 9.29% in the previous three trading sessions and 0.13% in the last one month. Additionally, the company's shares have surged 130.49% on YTD basis. Shares of the company are trading above their 50-day and 200-day moving averages of $6.78 and $4.06, respectively. Furthermore, Achillion Pharmaceuticals Inc.'s stock has an RSI of 60.81. Register for free on Investor-Edge and access the latest research on ACHN at:

http://www.Investor-Edge.com/ACHN-13Aug2014

XOMA Corp.'s stock declined 1.18% on Tuesday, closing the day at $4.17. The stock recorded a trading volume of 1.31 million shares, near its three months average volume of 1.43 million shares. The stock oscillated between $4.16 and $4.35 during the session. Shares in XOMA Corp. have advanced 7.20% in the previous three trading sessions, while the company's shares have fallen by 1.88% in the last one month and 38.04% since the start of this year. XOMA Corp.'s shares are trading below their 50-day and 200-day moving averages of $4.31 and $5.38, respectively. Additionally, the stock has an RSI of 54.65. The complete research on XOMA is available for free at:

http://www.Investor-Edge.com/XOMA-13Aug2014

Shares in Amicus Therapeutics Inc. edged 0.24% higher on Tuesday, closing the session at $4.16. A total of 1.21 million shares were traded, which was below its three months average volume of 1.57 million shares. The stock moved between $4.06 and $4.21 during the session. Amicus Therapeutics Inc.'s stock has gained 3.48% in the previous three trading sessions and 5.05% in the last one month. Additionally, the company's shares have surged 77.02% from the beginning of 2014. The company's stock is trading above its 50-day and 200-day moving averages of $3.54 and $2.59, respectively. Furthermore, Amicus Therapeutics Inc.'s stock has an RSI of 56.10. Free in depth research on FOLD is available at:

http://www.Investor-Edge.com/FOLD-13Aug2014

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Investor-Edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED